Westaim Corporation, founded in 1996 and based in Toronto, Canada, operates as a private equity firm focused on the financial services sector. The firm aims to provide capital appreciation and real wealth preservation for its shareholders through direct and indirect investments, including acquisitions and joint ventures. Westaim holds a significant interest in NUCRYST Pharmaceuticals Corp., reinforcing its commitment to strategic investments that align with its objectives.
NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.